News

Capricor Therapeutics Faces Class Action: Investor Options Ahead

Capricor Therapeutics Faces Class Action: Investor Options Ahead

Capricor Therapeutics Faces Class Action Lawsuit

Investors in Capricor Therapeutics, Inc. are currently facing the implications of a class action securities lawsuit. It's essential for stakeholders to understand the nature of this suit and the opportunities available for participation. The firm Levi & Korsinsky, LLP is spearheading this legal effort, reminding individuals of the approaching deadline to become involved.

Understanding the Class Action Lawsuit

This class action seeks to recover losses for investors adversely affected by alleged fraud. The claimed period of concern extends between October 9, 2024, and July 10, 2025. If you have been impacted by these events, it's crucial to assess whether you qualify to join this class action.

Who Is Affected?

This lawsuit is intended for those who purchased shares of Capricor during the specified timeframe. Investors should analyze their investment activity during this period to determine if they might be eligible for recovery. Many individuals might not be aware of their rights, but it's vital to understand that they can still take action.

Details of the Case

The crux of the lawsuit revolves around Capricor's lead cell therapy candidate drug, deramiocel, aimed at treating cardiomyopathy caused by Duchenne muscular dystrophy (DMD). The allegations contend that the company's management provided misleading information regarding the efficacy and approval status of this drug while withholding crucial details about safety outcomes from prior trials.

Recent Developments

A significant turning point occurred on July 11, 2025, when Capricor announced it received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for deramiocel. The agency's denial was based on insufficient evidence of effectiveness and the need for additional clinical data. After this announcement, the stock price saw a considerable drop, highlighting the financial impact of the situation.

What Investors Should Know

Investors who experienced financial losses during this period have until September 15, 2025, to apply to be designated as lead plaintiffs within this lawsuit. However, it's important to understand that participation in the suit does not require an individual to take on this role to benefit from any potential recovery.

No Fees for Participants

One encouraging aspect for investors is that participation in this class action may not incur any out-of-pocket expenses. Those eligible for compensation won’t face any costs or obligations for joining the suit, which presents a risk-free opportunity for recovering losses.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has a two-decade history of advocating for investors and securing significant settlements in securities litigation. The firm is known for its expertise in this legal field, offering dedicated services through a skilled team of over 70 professionals. Their experience has earned them recognition as one of the top securities litigation firms.

How to Reach Out

If you are an investor in Capricor and wish to learn more about your options or the lawsuit itself, contacting Levi & Korsinsky is an effective first step. Interested parties can reach Joseph E. Levi, Esq., via telephone or email for inquiries regarding the case.

Frequently Asked Questions

What is the purpose of the class action lawsuit?

The class action aims to recover financial losses for investors who suffered due to alleged fraudulent activities by Capricor concerning their lead therapy candidate.

Who can participate in the lawsuit?

Any investor who purchased shares of Capricor during the specified period of the alleged fraud may be eligible to participate in the lawsuit.

What do I need to do to join the class action?

To join, investors need to submit a request to the court to appoint them as lead plaintiffs before the deadline of September 15, 2025.

What happens after I join the lawsuit?

After joining, participants will await further instructions regarding the legal proceedings and potential compensation if the case results in a favorable outcome.

Are there any costs associated with joining the class action?

No, there are no out-of-pocket costs or fees for participants of the class action lawsuit.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Mobix Labs Achieves Record Growth with 50% Revenue Surge

Updated Category News Views 136

Mobix Labs Sees Remarkable Revenue Expansion Mobix Labs, Inc. (Nasdaq: MOBX), based in Irvine, California, is making headlines with a remarkable performance in its latest fiscal year. Having achieved over 50% revenue growth, the company has undeniably marked its footprint in the advanced connectivity market, providing essential solutions for industries like aerospace,...

Continue Reading
Strengthening Global Cooperation Through BRICS: Insights from Experts

Updated Category News Views 373

Building Bridges: The Role of BRICS in Global South Cooperation The ongoing evolution of global politics highlights the importance of platforms like BRICS, which have become pivotal in fostering solidarity among emerging economies. The 17th BRICS Summit recently placed a strong emphasis on sustainable development, opposition to unilateral trade measures, and the need for...

Continue Reading
ATP Secures Conditional Exemption Regarding Acquisition Deal

Updated Category News Views 133

ATP's Notification to Copenhagen Airports A/S In a significant development, Arbejdsmarkedets Tillægspension (ATP) has notified Copenhagen Airports A/S about receiving a conditional exemption from the Danish Financial Supervisory Authority (DFSA). This exemption relates to ATP's involvement in the indirect acquisition of a controlling share in Copenhagen Airports A/S....

Continue Reading
Adecco Group Reports Stable Q3 Performance Amid Challenges

Updated Category News Views 58

Adecco Group's Performance Analysis for Q3 2024 The Adecco Group continues to display a robust performance even amidst challenging market conditions. Recent results for the third quarter showcase the resilience of the organization, particularly with volumes stabilizing as the market evolves. Quarterly Revenue Insights In Q3 2024, Adecco reported a 5% year-over-year...

Continue Reading
Freeport-McMoRan Charts a Unique Course in Copper Production

Updated Category News Views 57

An Alternative Approach to Growth in the Mining Sector In a market where industry giants like BHP and Rio Tinto are actively pursuing mergers and acquisitions, Freeport-McMoRan (NYSE: FCX) is choosing a different path. The company is concentrated on fostering organic growth, prioritizing production increment over expensive acquisitions. Production Expansion Across...

Continue Reading